Please assess the completion status of the following clinical trial:

Trial Title: Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject \>= 18 years;~* Histologically or cytologically confirmed, metastatic or locally advanced unresectable HER2-positive;~* Adequate organ function assessed within 7 days prior to first trial treatment~* ECOG score 0 or 1;~* Left ventricular ejection fraction (LVEF) ≥ 50% at baseline;~* Life expectancy \>3 months~Exclusion Criteria:~* Untreated active CNS metastasis or leptomeningeal metastasis;~* Uncontrolled tumor-related pain;~* Has received other anti-tumor treatment or an investigational drug within 28 days or within 5 times of half-life (whichever is shorter, and no less than 2 weeks) prior to the first trial treatment;~* Major surgery for any reason within 28 days;~* Curative radiation within 3 months of the first dose of trial treatment;~* History of uncontrolled intercurrent illness;~* Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- dose-escalation Phase (Type: None): KN026 20 mg/kg + palbociclib125 mg/day+Fulvestrant 500 mg (Patients with HR+/HER2-positive MBC )
- parallel-group expansion Phase (Type: None): KN026 20 mg/kg + palbociclib +Fulvestrant 500 mg(Patients with HR+/HER2-positive MBC )

Based on this trial design, predict the completion outcome and termination type (if applicable).